ERBB2 and renal pelvis/ureter urothelial carcinoma: Irrespective of their ERBB2 status, patients with UTUC treated with platin showed a significantly lower PFS than UTUC patients who had not received any platin-based therapy, a result that persisted in the multiple regression approach.